Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms

被引:268
作者
Ariëns, RAS
Lai, TS
Weisel, JW
Greenberg, CS
Grant, PJ
机构
[1] Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA
[2] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA
[3] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA
[4] Univ Leeds, Sch Med, Acad Unit Mol Vasc Med, Leeds LS2 9JT, W Yorkshire, England
关键词
D O I
10.1182/blood.V100.3.743
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Factor XIII and fibrinogen are unusual among clotting factors in that neither is a serine protease. Fibrin is the main protein constituent of the blood clot, which is stabilized by factor XIIIa through an amide or isopeptide bond that ligates adjacent fibrin monomers. Many of the structural and functional features of factor XIII and fibrin(ogen) have been elucidated by protein and gene analysis, site-directed mutagenesis, and x-ray crystallography. However, some of the molecular aspects involved in the complex processes of insoluble fibrin formation in vivo and in vitro remain unresolved. The findings of a relationship between fibrinogen, factor XIII, and cardiovascular or other thrombotic disorders have focused much attention on these 2 proteins. Of particular interest are associations between common variations in the genes of factor XIII and altered risk profiles for thrombosis. Although there is much debate regarding these observations, the implications for our understanding of clot formation and therapeutic intervention may be of major importance. In this review, we have summarized recent findings on the structure and function of factor XIII. This is followed by a review of the effects of genetic polymorphisms on protein structure/function and their relationship to disease. (C) 2002 by The American Society of Hematology.
引用
收藏
页码:743 / 754
页数:12
相关论文
共 165 条
  • [1] Characterization of the reciprocal binding sites on human α-thrombin and factor XIII A-chain
    Achyuthan, KE
    [J]. MOLECULAR AND CELLULAR BIOCHEMISTRY, 1998, 178 (1-2) : 289 - 297
  • [2] GLY-PRO-ARG-PRO MODIFIES THE GLUTAMINE RESIDUES IN THE ALPHA-CHAIN AND GAMMA-CHAINS OF FIBRINOGEN - INHIBITION OF TRANSGLUTAMINASE CROSS-LINKING
    ACHYUTHAN, KE
    DOBSON, JV
    GREENBERG, CS
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1986, 872 (03) : 261 - 268
  • [3] CHARACTERIZATION OF FACTOR-XIII CONTAINING-MACROPHAGES IN LYMPH-NODES WITH HODGKINS-DISEASE
    ADANY, R
    NEMES, Z
    MUSZBEK, L
    [J]. BRITISH JOURNAL OF CANCER, 1987, 55 (04) : 421 - 426
  • [4] Factor XIIIA Val34Leu polymorphism does not predict risk of coronary heart disease - The Atherosclerosis Risk in Communities (ARIC) study
    Aleksic, N
    Ahn, C
    Wang, YW
    Juneja, H
    Folsom, AR
    Boerwinkle, E
    Wu, KK
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (02) : 348 - 352
  • [5] PLATELET FACTOR-XIII IS ACTIVATED BY CALPAIN
    ANDO, Y
    IMAMURA, S
    YAMAGATA, Y
    KITAHARA, A
    SAJI, H
    MURACHI, T
    KANNAGI, R
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1987, 144 (01) : 484 - 490
  • [6] MOLECULAR-BASIS OF INHERITED FACTOR-XIII DEFICIENCY - IDENTIFICATION OF MULTIPLE MUTATIONS PROVIDES INSIGHTS INTO PROTEIN FUNCTION
    ANWAR, R
    STEWART, AD
    MILOSZEWSKI, KJA
    LOSOWSKY, MS
    MARKHAM, AF
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1995, 91 (03) : 728 - 735
  • [7] Genotype/phenotype correlations for coagulation factor XIII: Specific normal polymorphisms are associated with high or low factor XIII specific activity
    Anwar, R
    Gallivan, L
    Edmonds, SD
    Markham, AF
    [J]. BLOOD, 1999, 93 (03) : 897 - 905
  • [8] The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure
    Ariens, RAS
    Philippou, H
    Nagaswami, C
    Weisel, JW
    Lane, DA
    Grant, PJ
    [J]. BLOOD, 2000, 96 (03) : 988 - 995
  • [9] Ashcroft AE, 2000, RAPID COMMUN MASS SP, V14, P1607, DOI 10.1002/1097-0231(20000915)14:17<1607::AID-RCM69>3.3.CO
  • [10] 2-C